Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Toshihiko Doi et al.|The Lancet Oncology|2023Cited by 195
Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or AchlorhydriaDawen Kou, Peter Yehl, Sudharsan Dwaraknath et al.|Molecular Pharmaceutics|2017Cited by 14